BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients.
Biomarkers
Bladder cancer
Cystoscopy
DNA methylation
Detection
Digital PCR
Hematuria
Methylome sequencing
Non-invasive detection
Urine test
Journal
Clinical epigenetics
ISSN: 1868-7083
Titre abrégé: Clin Epigenetics
Pays: Germany
ID NLM: 101516977
Informations de publication
Date de publication:
17 09 2022
17 09 2022
Historique:
received:
06
07
2022
accepted:
11
09
2022
entrez:
17
9
2022
pubmed:
18
9
2022
medline:
21
9
2022
Statut:
epublish
Résumé
Cystoscopy is the gold standard for bladder cancer detection, but is costly, invasive and has imperfect diagnostic accuracy. We aimed to identify novel and accurate DNA methylation biomarkers for non-invasive detection of bladder cancer in urine, with the potential to reduce the number of cystoscopies among hematuria patients. Biomarker candidates (n = 32) were identified from methylome sequencing of urological cancer cell lines (n = 16) and subjected to targeted methylation analysis in tissue samples (n = 60). The most promising biomarkers (n = 8) were combined into a panel named BladMetrix. The performance of BladMetrix in urine was assessed in a discovery series (n = 112), consisting of bladder cancer patients, patients with other urological cancers and healthy individuals, resulting in 95.7% sensitivity and 94.7% specificity. BladMetrix was furthermore evaluated in an independent prospective and blinded series of urine from patients with gross hematuria (n = 273), achieving 92.1% sensitivity, 93.3% specificity and a negative predictive value of 98.1%, with the potential to reduce the number of cystoscopies by 56.4%. We here present BladMetrix, a novel DNA methylation urine test for non-invasive detection of bladder cancer, with high accuracy across tumor grades and stages, and the ability to spare a significant number of cystoscopies among patients with gross hematuria.
Sections du résumé
BACKGROUND
Cystoscopy is the gold standard for bladder cancer detection, but is costly, invasive and has imperfect diagnostic accuracy. We aimed to identify novel and accurate DNA methylation biomarkers for non-invasive detection of bladder cancer in urine, with the potential to reduce the number of cystoscopies among hematuria patients.
RESULTS
Biomarker candidates (n = 32) were identified from methylome sequencing of urological cancer cell lines (n = 16) and subjected to targeted methylation analysis in tissue samples (n = 60). The most promising biomarkers (n = 8) were combined into a panel named BladMetrix. The performance of BladMetrix in urine was assessed in a discovery series (n = 112), consisting of bladder cancer patients, patients with other urological cancers and healthy individuals, resulting in 95.7% sensitivity and 94.7% specificity. BladMetrix was furthermore evaluated in an independent prospective and blinded series of urine from patients with gross hematuria (n = 273), achieving 92.1% sensitivity, 93.3% specificity and a negative predictive value of 98.1%, with the potential to reduce the number of cystoscopies by 56.4%.
CONCLUSIONS
We here present BladMetrix, a novel DNA methylation urine test for non-invasive detection of bladder cancer, with high accuracy across tumor grades and stages, and the ability to spare a significant number of cystoscopies among patients with gross hematuria.
Identifiants
pubmed: 36115961
doi: 10.1186/s13148-022-01335-2
pii: 10.1186/s13148-022-01335-2
pmc: PMC9482155
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
115Informations de copyright
© 2022. The Author(s).
Références
J Urol. 2010 Jan;183(1):76-80
pubmed: 19913254
Clin Epigenetics. 2017 Jan 31;9:8
pubmed: 28163793
Epigenomics. 2018 May;10(5):673-687
pubmed: 29692199
Clin Chem. 2020 Aug 1;66(8):1012-1029
pubmed: 32746458
Clin Cancer Res. 2010 Dec 1;16(23):5842-51
pubmed: 20975101
Eur Urol. 2016 Dec;70(6):916-919
pubmed: 27417036
Eur Urol. 2022 Jan;81(1):75-94
pubmed: 34511303
Epigenetics. 2012 Nov;7(11):1249-57
pubmed: 22983262
PLoS One. 2015 Jul 07;10(7):e0131889
pubmed: 26151138
Diagnostics (Basel). 2020 Jan 13;10(1):
pubmed: 31941070
Clin Chem. 2015 Dec;61(12):1446-52
pubmed: 26510957
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
J Urol. 2016 Mar;195(3):601-7
pubmed: 26327355
Eur Urol. 2017 Mar;71(3):447-461
pubmed: 27324428
Eur Urol. 2014 Aug;66(2):253-62
pubmed: 24472711
J Urol. 2017 Mar;197(3 Pt 1):590-595
pubmed: 27746284
Eur Urol Oncol. 2021 Dec;4(6):927-942
pubmed: 34753702
Bladder Cancer. 2018 Oct 29;4(4):353-363
pubmed: 30417046
Int J Mol Sci. 2019 May 30;20(11):
pubmed: 31151158
Ann Intern Med. 2015 Dec 15;163(12):922-31
pubmed: 26501851
Urology. 2017 Feb;100:20-26
pubmed: 27645524
Clin Epigenetics. 2018 Feb 21;10:24
pubmed: 29484034
BMJ. 2013 May 16;346:f2778
pubmed: 23682043
Hepatology. 2015 May;61(5):1651-9
pubmed: 25644509
J Urol. 2007 Jul;178(1):62-7
pubmed: 17499283
Nat Rev Urol. 2013 Jun;10(6):327-35
pubmed: 23628807
BJU Int. 2016 May;117(5):783-6
pubmed: 26435378
Mol Cancer. 2011 Jul 21;10:85
pubmed: 21777459
Cancers (Basel). 2021 Aug 30;13(17):
pubmed: 34503188
Health Technol Assess. 2010 Jan;14(4):1-331, iii-iv
pubmed: 20082749
J Biotechnol. 2012 Jan;157(1):1-6
pubmed: 21763364
J Urol. 2007 Apr;177(4):1277-82; discussion 1282
pubmed: 17382711
Expert Rev Anticancer Ther. 2008 Jul;8(7):1111-23
pubmed: 18588456
Eur Urol. 2022 Aug;82(2):182-192
pubmed: 35393159
Urology. 2000 Nov 1;56(5):793-7
pubmed: 11068304